Biomarkers for multiple sclerosis

Drug News and Perspectives

Volumn 23, Issue 9, 2010, Pages 582-595

  Villoslada, Pablo ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; GADOLINIUM; HLA ANTIBODY; MYELIN; BIOLOGICAL MARKER;

CEREBROSPINAL FLUID ANALYSIS; CLINICAL INDICATOR; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DISEASE COURSE; HUMAN; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL COHERENCE TOMOGRAPHY; PROGNOSIS; QUALITY OF LIFE; RATING SCALE; RELAPSE; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE;

BIOLOGICAL MARKERS; HUMANS; INDIVIDUALIZED MEDICINE; MULTIPLE SCLEROSIS; PROGNOSIS; QUALITY OF LIFE; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 79952279448     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2010.23.9.1472300     Document Type: Review

References (86)

1. Rees, J. Complex disease and the new clinical sciences. Science 2002, 296(5568): 698-700.
2. Trusheim, M.R., Berndt, E.R., Douglas, F.L. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007, 6(4): 287-93. (Pubitemid 46505879)
3. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69(3): 89-95.
4. Prentice, R.L. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989, 8(4): 431-40. (Pubitemid 19105891)
5. Bielekova, B., Martin, R. Development of biomarkers in multiple sclerosis. Brain 2004, 127(Pt 7): 1463-78. (Pubitemid 38899400)
6. Sawyers, C.L. The cancer biomarker problem. Nature 2008, 452(7187): 548-52. (Pubitemid 351483368)
7. Villoslada, P., Steinman, L., Baranzini, S.E. Systems biology and its application to the understanding of neurological diseases. Ann Neurol 2009, 65(2): 124-39.
8. FDA, Guidance for Industry: Pharmacogenomic Data Submissions. U.S. FDA, Washington, D.C., 2005.
9. Bossuyt, P.M., Reitsma, J.B., Bruns, D.E. et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 2003, 49(1): 7-18. (Pubitemid 36078547)
10. McShane, L.M., Altman, D.G., Sauerbrei, W., Taube, S.E., Gion, M., Clark, G.M. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2005, 2(8): 416-22. (Pubitemid 43115010)
11. Polman, C.H., Reingold, S.C., Edan, G. et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005, 58(6): 840-6.
12. Montalban, X., Tintore, M., Swanton, J. et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 2010, 74(5): 427-34.
13. Janssens, A.C., van Doorn, P.A., de Boer, J.B., van der Meche, F.G., Passchier, J., Hintzen, R.Q. Perception of prognostic risk in patients with multiple sclerosis: the relationship with anxiety, depression, and disease-related distress. J Clin Epidemiol 2004, 57(2): 180-6. (Pubitemid 38668612)
14. Tumani, H., Hartung, H.P., Hemmer, B., Teunissen, C., Deisenhammer, F., Giovannoni, G., Zettl, U.K. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis 2009, 35(2): 117-27.
15. Reindl, M., Khalil, M., Berger, T. Antibodies as biological markers for pathophysiological processes in MS. J Neuroimmunol 2006, 180(1-2): 50-62. (Pubitemid 44692320)
16. Ibrahim, S.M., Gold, R. Genomics, proteomics, metabolomics: what is in a word for multiple sclerosis? Curr Opin Neurol 2005, 18(3): 231-5.
17. Villar, L.M., Garcia-Barragan, N., Sadaba, M.C. et al. Accuracy of CSF and MRI criteria for dissemination in space in the diagnosis of multiple sclerosis. J Neurol Sci 2008, 266(1- 2): 34-7. (Pubitemid 351186516)
18. Tintore, M., Rovira, A., Rio, J. et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 2007, 70(13): 1079-83.
19. Villar, L.M., Sadaba, M.C., Roldan, E. et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 2005, 115(1): 187-94. (Pubitemid 40385520)
20. Thangarajh, M., Gomez-Rial, J., Hedstrom, A.K., Hillert, J., Alvarez-Cermeno, J.C., Masterman, T., Villar, L.M. Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis. Mult Scler 2008, 14(9): 1208-13.
21. Oksenberg, J.R., Baranzini, S.E., Sawcer, S., Hauser, S.L. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 2008, 9(7): 516-26. (Pubitemid 351861542)
22. Fugger, L., Friese, M.A., Bell, J.I. From genes to function: the next challenge to understanding multiple sclerosis. Nat Rev Immunol 2009, 9(6): 408-17.
23. Barcellos, L.F., Sawcer, S., Ramsay, P.P. et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 2006, 15(18): 2813-24. (Pubitemid 44400408)
24. Pappas, D.J., Oksenberg, J.R. Multiple sclerosis pharmacogenomics: maximizing efficacy of therapy. Neurology, 74 Suppl 1: S62-9.
25. Martinez-Forero, I., Pelaez, A., Villoslada, P. Pharmacogenomics of multiple sclerosis: in search for a personalized therapy. Expert Opin Pharmacother 2008, 9(17): 3053-67.
26. Baranzini, S.E., Mousavi, P., Rio, J. et al. Transcription-based prediction of response to IFNbeta using supervised computational methods. PLoSBiol 2005, 3(1): e2.
27. Byun, E., Caillier, S.J., Montalban, X. et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 2008, 65(3): E1-E8.
28. O'Doherty, C., Favorov, A., Heggarty, S. et al. Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients. Pharmacogenomics 2009, 10(7): 1177-86.
29. Grossman, I., Avidan, N., Singer, C. et al. Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers. Pharmacogenet Genomics 2007, 17(8): 657-66. (Pubitemid 47057715)
30. Berger, T., Reindl, M. Biomarkers in multiple sclerosis: role of antibodies. Dis Markers 2006, 22(4): 207-12. (Pubitemid 44763274)
31. Lalive, P.H., Menge, T., Delarasse, C. et al. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci U S A 2006, 103(7): 2280-5. (Pubitemid 43271661)
32. Polman, C.H., Killestein, J. Anti-myelin antibodies in multiple sclerosis: clinically useful? J Neurol Neurosurg Psychiatry 2006, 77(6): 712.
33. McKeon, A., Fryer, J.P., Apiwattanakul, M. et al. Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol 2009, 66(9): 1134-8.
34. Sospedra, M., Martin, R. Immunology of multiple sclerosis. Annu Rev Immunol 2005, 23: 683-747. (Pubitemid 40563183)
35. Hauser, S.L., Oksenberg, J.R. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006, 52(1): 61-76. (Pubitemid 44466355)
36. Han, M.H., Hwang, S., Roy, D.B. et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets in the coagulation cascade. Nature 2007, 451: 1076-81. (Pubitemid 351317445)
37. Berven, F.S., Flikka, K., Berle, M., Vedeler, C., Ulvik, R.J. Proteomic-based biomarker discovery with emphasis on cerebrospinal fluid and multiple sclerosis. Curr Pharm Biotechnol 2006, 7(3): 147-58. (Pubitemid 43881079)
38. Ottervald, J., Franzen, B., Nilsson, K. et al. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers. J Proteomics 2010, 73(6): 1117-32.
39. Satoh, J.I., Tabunoki, H., Yamamura, T. Molecular network of the comprehensive multiple sclerosis brain-lesion proteome. Mult Scler 2009, 15(5): 531-41.
40. Stoop, M.P., Dekker, L.J., Titulaer, M.K. et al. Quantitative matrix-assisted laser desorption ionization-fourier transform ion cyclotron resonance (MALDI-FT-ICR) peptide profiling and identification of multiple-sclerosis-related proteins. J Proteome Res 2009, 8(3): 1404-14.
41. Sinclair, A.J., Viant, M.R., Ball, A.K. et al. NMR-based metabolomic analysis of cerebrospinal fluid and serum in neurological diseases - a diagnostic tool? NMR Biomed 2010, 18: 41.
42. Ascherio, A., Munger, K.L. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol 2007, 61(6): 504-13.
43. Kanter, J.L., Narayana, S., Ho, P.P. et al. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat Med 2006, 12(1): 138-43. (Pubitemid 43050089)
44. Podbielska, M., Hogan, E.L. Molecular and immunogenic features of myelin lipids: incitants or modulators of multiple sclerosis? Mult Scler 2009, 15(9): 1011-29.
45. An, H.J., Kronewitter, S.R., de Leoz, M.L., Lebrilla, C.B. Glycomics and disease markers. Curr Opin Chem Biol 2009, 13(5-6): 601-7.
46. Quintana, F.J., Farez, M.F., Viglietta, V. et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A 2008, 105(48): 18889-94.
47. Kasper, L.H., Shoemaker, J. Multiple sclerosis immunology: The healthy immune system vs the MS immune system. Neurology 74(Suppl. 1): S2-8.
48. Venken, K., Hellings, N., Liblau, R., Stinissen, P. Disturbed regulatory T cell homeostasis in multiple sclerosis. Trends Mol Med, 16(2): 58-68.
49. Martinez-Forero I, Garcia-Munoz R, Martinez-Pasamar A et al. IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in Multiple Sclerosis. Eur J Immunol 2008, 38(2): 576-86.
50. Zozulya, A.L., Wiendl, H. The role of regulatory T cells in multiple sclerosis. Nat Clin Pract Neurol 2008, 4(7): 384-98. (Pubitemid 352003290)
51. Ascherio, A., Munger, K.L. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007, 61(4): 288-99.
52. Fotheringham, J., Jacobson, S. Human herpesvirus 6 and multiple sclerosis: potential mechanisms for virus-induced disease. Herpes 2005, 12(1): 4-9. (Pubitemid 40863380)
53. Villoslada, P., Juste, C., Tintore, M., Llorenc, V., Codina, G., Pozo-Rosich, P., Montalban, X. The immune response against herpesvirus is more prominent in the early stages of MS. Neurology 2003, 60(12): 1944-8. (Pubitemid 36736010)
54. Lunemann, J.D., Ascherio, A. Immune responses to EBNA1: biomarkers in MS? Neurology 2009, 73(1): 13-4.
55. Alvarez-Lafuente, R., Garcia-Montojo, M., De Las Heras, V., Dominguez-Mozo, M.I., Bartolome, M., Benito-Martin, M.S., Arroyo, R. Herpesviruses and human endogenous retroviral sequences in the cerebrospinal fluid of multiple sclerosis patients. Mult Scler 2008, 14(5): 595-601. (Pubitemid 351954400)
56. Alvarez-Lafuente, R., Garcia-Montojo, M., De las Heras, V., Bartolome, M., Arroyo, R. Clinical parameters and HHV-6 active replication in relapsing-remitting multiple sclerosis patients. J Clin Virol 2006, 37(Suppl. 1): S24-6.
57. Brettschneider, J., Petzold, A., Junker, A., Tumani, H. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult Scler 2006, 12(2): 143-8.
58. Hein Nee Maier, K., Kohler, A., Diem, R. et al. Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis. Neurosci Lett 2008, 436(1): 72-6.
59. Teunissen, C., Dijkstra, C.D., Polman, C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 2005, 4(1): 32-41. (Pubitemid 40023234)
60. Teunissen, C.E., Petzold, A., Bennett, J.L. et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009, 73(22): 1914-22.
61. Giovannoni, G., Thompson, E.J. Urinary markers of disease activity in multiple sclerosis. Mult Scler 1998, 4(3): 247-53. (Pubitemid 28410060)
62. Malcus-Vocanson, C., Giraud, P., Broussolle, E., Perron, H., Mandrand, B., Chazot, G. A urinary marker for multiple sclerosis. Lancet 1998, 351(9112): 1330. (Pubitemid 28195916)
63. Dobson, R., Miller, R.F., Palmer, H.E. et al. Increased urinary free immunoglobulin light chain excretion in patients with multiple sclerosis. J Neuroimmunol 2010, 220(1-2): 99-103.
64. 't Hart, B.A., Vogels, J.T., Spijksma, G., Brok, H.P., Polman, C., van der Greef, J. 1H-NMR spectroscopy combined with pattern recognition analysis reveals characteristic chemical patterns in urines of MS patients and non-human primates with MS-like disease. J Neurol Sci 2003, 212(1-2): 21-30.
65. Barkhof, F., Filippi, M. MRI-the perfect surrogate marker for multiple sclerosis? Nat Rev Neurol 2009, 5(4): 182-3.
66. Tintore, M., Rovira, A., Martinez, M.J. et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR 2000, 21(4): 702-6. (Pubitemid 30210434)
67. Miller, D.H. Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis. NeuroRx 2004, 1(2): 284-94.
68. Barkhof, F., Calabresi, P.A., Miller, D.H., Reingold, S.C. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009, 5(5): 256-66.
69. Zhang, Y., Zhu, H., Mitchell, J.R., Costello, F., Metz, L.M. T2 MRI texture analysis is a sensitive measure of tissue injury and recovery resulting from acute inflammatory lesions in multiple sclerosis. Neuroimage 2009, 47(1): 107-11.
70. Filippi, M., Agosta, F. Magnetization transfer MRI in multiple sclerosis. J Neuroimaging 2007, 17(Suppl. 1): 22S-6S.
71. De Stefano, N., Filippi, M. MR spectroscopy in multiple sclerosis. J Neuroimaging 2007, 17(Suppl. 1): 31S-5S.
72. Rovaris, M., Agosta, F., Pagani, E., Filippi, M. Diffusion tensor MR imaging. Neuroimaging Clin N Am 2009, 19(1): 37-43.
73. Esteban, F., Sepulcre, J., Ruiz de Miras, J. et al. Fractal dimension analysis of grey matter in multiple sclerosis J Neurol Sci 2009, 282(1-2): 67-71.
74. Esteban, F.J., Sepulcre, J., de Mendizabal, N.V. et al. Fractal dimension and white matter changes in multiple sclerosis. Neuroimage 2007, 36(3): 543-9. (Pubitemid 46907639)
75. Frohman, E.M., Fujimoto, J.G., Frohman, T.C., Calabresi, P.A., Cutter, G., Balcer, L.J. Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol 2008, 4(12): 664-75.
76. Sepulcre, J., Murie-Fernandez, M., Salinas-Alaman, A., Garcia-Layana, A., Bejarano, B., Villoslada, P. Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS. Neurology 2007, 68(18): 1488-94. (Pubitemid 46685919)
77. Menke, M.N., Dabov, S., Knecht, P., Sturm, V. Reproducibility of retinal thickness measurements in healthy subjects using spectralis optical coherence tomography. Am J Ophthalmol 2009, 147(3): 467-72.
78. Confavreux, C., Vukusic, S. Natural history of multiple sclerosis: a unifying concept. Brain 2006, 129(Pt 3): 606-16. (Pubitemid 43278223)
79. Baier, M.L., Cutter, G.R., Rudick, R.A. et al. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology 2005, 64(6): 992-5. (Pubitemid 40388449)
80. Leocani, L., Comi, G. Neurophysiological markers. Neurol Sci 2008, 29(Suppl. 2): S218-21.
81. Villoslada, P., Oksenberg, J. Neuroinformatics in clinical practice: are computers going to help neurological patients and their physicians? Future Neurology 2006, 1(2): 1-12.
82. Bates, D.W., Gawande, A.A. Improving safety with information technology. N Engl J Med 2003, 348(25): 2526-34. (Pubitemid 36706541)
83. Tegner, J.N., Compte, A., Auffray, C. et al. Computational disease modeling - fact or fiction? BMC Syst Biol 2009, 3: 56.
84. Villoslada, P., Oksenberg, J.R., Rio, J., Montalban, X. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2004, 62(9): 1653. (Pubitemid 38608225)
85. Rio, J., Comabella, M., Montalban, X. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol 2009, 5(10): 553-60.
86. O'Doherty, C., Villoslada, P., Vandenbroeck, K. Pharmacogenomics of Type I interferon therapy: a survey of response-modifying genes. Cytokine Growth Factor Rev 2007, 18(3-4): 211-22. (Pubitemid 46900903)